Oncopeptides AB (publ) (LON:0RN4)

Market Cap	28.96M
Revenue (ttm)	3.07M
Net Income (ttm)	-21.40M
Shares Out	n/a
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	3,968
Open	n/a
Previous Close	1.868
Day's Range	n/a
52-Week Range	1.292 - 3.600
Beta	n/a
RSI	37.64
Earnings Date	May 15, 2025

About Oncopeptides AB

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Its PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic m...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 80
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RN4

Financial Performance

In 2024, Oncopeptides AB's revenue was 31.65 million, a decrease of -10.14% compared to the previous year's 35.22 million. Losses were -284.61 million, 14.2% more than in 2023.

Financial numbers in SEK